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Renal cell carcinoma (RCC) has long been termed a
radioresistant histology owing to older data demonstrating
a lack of benefit with conventional fractionated radia-
tion.1,2 More modern series have demonstrated that high-
dose regimens delivered using stereotactic body radiation
therapy (SBRT) offer impressive tumor control.3,4 Pres-
ervation of normal kidney function is a priority when
using radiation therapy (RT). Investigators have previ-
ously noted decreased renal function after SBRT, espe-
cially in patients with pre-existing renal disease.5,6 The
effectiveness of SBRT correlates with accurate tumor
delineation and avoidance of high-dose radiation to
normal tissue. Furthermore, treatment planning must
compensate for respiratory motion of renal tumors.
We report a case illustrating a patient with metastatic
RCC who responded on systemic therapy with nivolumab
and underwent SBRT to the primary renal mass for a
cytoreductive effect. This SBRT regimen was delivered
using a magnetic resonance (MR) imaging (MRI)-guided
RT system that allows for MR-based simulation imaging,
real-time tumor tracking, and respiratory gating. We
further highlight the implications of this novel system in
treatment planning, treatment delivery, and potential
outcomes.
Case Report
An 83-year-old man presented to the emergency
department with acute shortness of breath and history of
progressive dyspnea over the prior 2 months. A computed
tomography (CT) scan of the chest revealed a large right-
sided pleural effusion, multiple bilateral pulmonary nod-
ules, and a superior left kidney lesion. The patient
received a thoracentesis with removal of 1.5 L of pleural
fluid and a biopsy of a right-sided pleural based nodule
via CT guidance. Pathology confirmed a diagnosis of
clear cell RCC, and pazopanib was initiated. After
2 months of therapy, the patient developed elevated
transaminases indicative of pazopanib-induced hepato-
toxicity. His systemic therapy was subsequently switched
to nivolumab.
Approximately 4 months after diagnosis, the patient
developed 4 brain metastases, which were treated with
stereotactic radiosurgery. After 1 year of nivolumab, the
patient was reimaged and found to have resolution of
intracranial disease, stable pulmonary nodules, response
of the primary left kidney mass, and no radiographic
evidence of new sites of disease. Given that the largest
burden of disease was in the left kidney, cytoreductive
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nephrectomy was discussed, but the patient declined
surgery. After 29 cycles of nivolumab, his disease
remained stable (Fig. 1A and 1B), and he consented to
local treatment of the left renal primary using SBRT.
The patient’s baseline renal function was assessed
using a renal scintigraphy before starting SBRT. The left
kidney contributed 34% of total renal function. In addi-
tion, baseline creatinine was 1.20 mg/dL, and estimated
glomerular filtration rate was 55 mL/min/1.73 m2.
Stereotactic body radiation therapy
The patient received a 4-dimensional CT simulation
lying supine in a body immobilization device with the left
arm up. MRI coils were placed under the immobilization
device, and the patient received MR simulation with the
MRI-guided RT system (ViewRay MRIdian System,
Oakwood Village, OH). CT and MR images were trans-
ferred to the RT planning system, where images were
registered and contouring was performed. The primary
contouring dataset was the MRI data obtained using a fast
gradient echo sequence (TrueFISP) as set by the manu-
facturer of the MRI-guided RT system. The treating ra-
diation oncologist contoured the gross tumor volume
(GTV), defined as the left kidney mass visible on the MRI
set. Planning tumor volume (PTV) was created using a
margin of 5 mm (Fig. 2A and 2B). Organs at risk (OARs)
were also delineated and included stomach, small bowel,
large bowel, kidneys, liver, and spinal cord.
An SBRT treatment plan was developed to deliver
4000 cGy in 5 daily fractions (Fig. 2C and 2D). Dose
constraints were used during planning for the following
OARs: stomach (V36 Gy [OAR volume receiving 36 Gy]
<0.5 mL, V18 Gy < 10 mL), small bowel
(V20 Gy < 5 mL, Dmax [maximum dose to volume]
<35 Gy), large bowel (V36 Gy < 0.5 mL,
V25 Gy < 20 mL), kidneys (V16 Gy < 60%), liver (mean
dose <18 Gy, V21 Gy < 700 mL), and spinal cord
(V25 Gy < 0.5 mL). The treatment was prescribed with
purposeful hotspots within the GTV. PTV coverage was
not compromised due to OARs. The treatment plan
delivered 95% prescription dose to 99% of the PTV. OAR
doses were as follows: stomach (V36 Gy Z 0 mL,
V18 GyZ 6 mL), small bowel (V20 GyZ 0 mL), large
bowel (V36 Gy Z 0 mL, V25 Gy Z 0 mL), kidneys
(V16 Gy Z 10%), liver (mean dose Z 2 Gy,
V21 Gy Z 0 cmL), and spinal cord (V25 Gy Z 0 mL).
All treatments were performed on the MRI-guided RT
machine using a 0.35T magnet, Co-60 delivery, and real-
time MRI acquisition. During daily set-up for treatment, a
volumetric MRI was obtained to visualize the left kidney
Figure 1 (A) Axial computed tomography (CT) scan of an abdomen demonstrating a 4.3  5.6 cm exophytic mass in the upper pole
of the left kidney with internal calcifications before radiation. (B) Coronal view of the CT scan of the abdomen before radiation.
(C) Axial CT scan of the abdomen after radiation demonstrating stable size of primary renal mass. (D) Coronal view of CT scan of the
abdomen after radiation.
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and OARs. RT was delivered using the end-expiration
gating technique. The treatment target was the GTV with a
5-mm expansion acting as the gating boundary (same as
PTV). Typical gating margins are 3 to 5 mm. The treating
physician selected a larger gating margin so that beam-off
time could be minimized. This was an important consid-
eration for an elderly patient who had difficulty maintain-
ing arm-up position for substantial treatment durations.
Figure 3A demonstrates the GTV within the gating
boundary resulting in radiation delivery, and Figure 3B
demonstrates the GTV moving outside the boundary
resulting in the beams turning off and temporarily stopping
delivery. The average delivery time for each fraction was
14.8 minutes, and the average on-table time for the patient
was 33 minutes. The average duty cycle was 75%.
During treatment, the patient experienced some mild
fatigue but did not report any nausea, vomiting, diarrhea,
or skin irritation. He presented for follow-up at 5 weeks
after completion of therapy and continued to report
fatigue without any new symptoms. CT of the chest,
abdomen, and pelvis was performed at 6 weeks, demon-
strating stable size of the primary renal mass and stable
metastatic disease. At 8 weeks after RT, the patient
decided to stop nivolumab because of continued fatigue
on therapy and proceeded with close observation. Imag-
ing was repeated at 6 months after RT and demonstrated
stable disease at the primary (Fig. 1C and 1D) and met-
astatic sites. In addition, the patient received a repeat
evaluation of his kidney function after SBRT. At
6 months after treatment, the patient’s kidney function
remained stable with creatinine of 1.20 mg/dL and esti-
mated glomerular filtration rate of 54 mL/min/1.73 m2.
Discussion
Cytoreductive nephrectomy in certain subgroups of
patients with metastatic RCC may improve overall
Figure 2 (A) Axial simulation magnetic resonance imaging (MRI) scan of the abdomen demonstrating gross tumor volume (GTV)
shaded in light green and planning target volume (PTV) in light blue. (B) Coronal view of MRI scan of the abdomen with treatment
volumes. (C) Axial MRI scan of the abdomen with treatment volumes and isodose lines: blue, 120%; orange, 100%; magenta, 80%.
(D) Coronal view of MRI scan of the abdomen with treatment volumes and isodose lines.
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survival. Flanigan et al performed a randomized trial
demonstrating that surgery followed by interferon therapy
improved survival over interferon therapy alone.7 Mick-
isch et al demonstrated favorable time to progression and
survival outcomes in the combined surgery and interferon
arm of their study as well.8 However, both studies were
performed before the advent of modern targeted systemic
therapy options. Although there is no published ran-
domized evidence to support cytoreductive surgery in
patients receiving targeted therapies, large modern retro-
spective studies have demonstrated survival outcomes
favoring surgery in this setting.9,10 However, patients
with RCC with brain metastases generally have a guarded
prognosis, and invasive surgery may not be a viable op-
tion for this subset of patients. Alternatives to surgery
include cryoablation and radiofrequency ablation, but
these are limited to smaller tumor volumes and are still
invasive procedures.11 Thus, in patients who are medi-
cally inoperable or decline invasive procedures, SBRT
may be an option to deliver noninvasive therapy to the
primary renal tumor.
Currently, SBRT is a feasible treatment modality for
nonmetastatic RCC, as described by the International
Radiosurgery Oncology Consortium for Kidney
consensus statement, and provides excellent long-term
local control.12,13 This technique allows for high doses of
radiation to be delivered to the tumor while attempting to
spare surrounding normal tissue. Most RT clinics use
fluoroscopic imaging and cone beam CT to help align
patients for SBRT treatments. Unfortunately, the ability of
both prior imaging modalities to discern tumor from
normal kidney and surrounding OARs can be poor in the
abdomen.14 MRI-guided RT provides excellent soft-tissue
contrast, which reduces this uncertainty. In addition to
improving accuracy of patient set-up, MRI can be
continuously acquired during treatment, without addi-
tional ionizing radiation, to confirm tumor location within
the gating boundary when the beam is on. This eliminates
the need for fiducial marker placement in a classically
highly vascular tumor. Treatment with this novel system
may improve the therapeutic ratio by improving tumor
coverage while reducing unnecessary dose to OARs. This
is of particular importance with SBRT treatments where
high doses of radiation are delivered with sharp dose fall
off outside the target volumes.
This case demonstrates that MRI-guided SBRT is a
reasonable approach to locally ablate the primary renal
tumor in the setting of stable metastatic RCC with con-
current nivolumab. Kerkhof et al initially reported the
technical feasibility of MRI-guided radiation for renal
tumor ablation by evaluating renal movement during free-
breathing and breath-hold imaging.15 Correa et al reported
a prospective phase 1 dose-escalation study for conven-
tional SBRT to the primary renal mass in metastatic pa-
tients with RCC; they were able to escalate to a regimen
of 35 Gy delivered in 5 fractions with acceptable toxicity
outcomes.16 Our patient was treated to 40 Gy in 5 frac-
tions with no reported toxicity at 6-month follow-up,
stable renal function, and no evidence of progression.
Of note, the benefits of SBRT may go beyond local
control. Radiation delivered in large fraction sizes is
known to boost the antitumor immune response in pre-
clinical studies.17,18 Singh et al showed that SBRT to the
primary renal mass in patients with metastatic RCC can
alter immunomodulatory markers in the primary tumor.19
The combination of high dose per fraction and immuno-
therapy in animal models has demonstrated responses in
both irradiated and nonirradiated sites of disease, sug-
gesting a role for SBRT in improving local and distant
control.20 As a result, prospective clinical evaluation of
the combination of SBRT with immunotherapy in patients
with RCC is underway (NCT02855203).
To our knowledge, this is the first report of MRI-
guided SBRT for the primary mass in a patient with
metastatic RCC. A prior case report demonstrated use of
the MRI-guided system on a spleen tumor with a more
conventionally fractionated radiation regimen.21 In the
present report, we detail the simulation and treatment
Figure 3 Sagittal magnetic resonance image view of respiratory-gated radiation delivery with gross tumor volume (yellow) within
3-mm gating boundary (light blue) (A) and outside gating boundary (B).
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planning parameters used for MRI-guided SBRT to the
kidney at our institution. Additional prospective studies
are needed to identify subgroups of patients with RCC
who may benefit from SBRT to not only metastatic dis-
ease, but also the primary site.
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